Is the business good?
How good a business is AMRX?
Amneal Pharmaceuticals, Inc. earns 15% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
15%
Return on invested capital · cost of capital 9.0% · 5.8 points above what the capital costs: growth creates value
- Operating margin
- 14%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q1 2026
- Cash conversion
- 1.97×
Cash conversion · every dollar of reported profit arrived as cash, and more
- Share count, year on year
- +1.5%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2020 | 4.6% |
| FY2021 | 7.3% |
| FY2022 | −4.3% |
| FY2023 | 8.5% |
| FY2024 | 8.9% |
| FY2025 | 13% |
Details›
- Gross margin12 months to Q1 2026
- 39%
- Operating margin12 months to Q1 2026
- 14%
- Net margin12 months to Q1 2026
- 4.0%
- Free cash flow margin
- 7.9%
- R&D as % of revenue
- 6.1%
- Revenue, trailing twelve months
- $3.05B
- Free cash flow, trailing twelve months
- $241M
- Net income, trailing twelve months
- $122M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 15%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #22 of 28 by Smart Score